Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
August 11, 2017 07:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Positive Data from Ongoing Phase 2 Study of SEL-212 Reported at Clinical Meetings in June 2017Further Preclinical Data Confirm Immune Tolerance Platform’s Broad PotentialRecent Financing Extends Cash...
August 04, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Report Second Quarter 2017 Financial Results on Friday, August 11, 2017

WATERTOWN, Mass., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
August 02, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2017

WATERTOWN, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
June 26, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces $50 Million Private Placement

WATERTOWN, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
June 19, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors

WATERTOWN, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
June 15, 2017 07:30 ET | Source: Selecta Biosciences

Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout

WATERTOWN, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
June 06, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Upcoming Clinical Presentations

WATERTOWN, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
May 31, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 7, 2017

WATERTOWN, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
May 15, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Proof of Concept for Rare Disease Methymalonic Acidemia (MMA) Gene TherapyGene Therapy Dose Titration Enabled via SVP-Rapamycin Combination Treatment WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE)...